Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 52,312 shares at $64.97 ($3.4M) on 2025-11-20, disclosed to the SEC on 2025-11-24.
Scheduled sale ($3.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $64.97 | 6,401 | $416K | 12.1% |
| 2 | $64.97 | 6,401 | $416K | 12.1% |
| 3 | $65.90 | 14,299 | $942K | 27.4% |
| 4 | $65.90 | 14,299 | $942K | 27.4% |
| 5 | $66.71 | 5,456 | $364K | 10.6% |
| 6 | $66.71 | 5,456 |
| $364K |
| 10.6% |
| Total | $65.84 avg | 52,312 | $3.4M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |